After Adverse Effects, Roche Ends Trials of Diabetes Drug
Roche has ended late-stage clinical trials that involved giving patients its experimental diabetes treatment taspoglutide. Data from 52 weeks of trials show that the drug, given once weekly by injection, caused a high rate of adverse reactions and led to a higher-than-expected rate of discontinuations. Some patients who took the drug reported gastrointestinal intolerability and serious hypersensitivity reactions. “These discontinuation rates compromise interpretation of the long-term safety data from the T-emerge studies, therefore continuing treatment with the current taspoglutide formulation is not considered to be in the best interest of patients,” Roche said. Roche has said it is considering a reformulation of the drug.
(c)
Similar Posts:
- Phase III efficacy data on bevacizumab plus chemotherapy in early breast cancer to be presented
- Hearing may be end of road for breast cancer drug
- Addition of exenatide to obese insulin-treated patients can improve glycemia and weight but is less well tolerated
- A Lot of Choice in Diabetes Medications
- CDC Wants Only High-Risk MSM Using PrEP
Recent Comments